ABSTRACT
BACKGROUND: Cutaneous leishmaniasis (CL) is a world-wide health problem which currently lacks effective, affordable and easy to use therapy. Recently, the meglumine antimoniate (MA) intralesional infiltration was included among the acceptable therapies for New World leishmaniasis. While this approach is attractive, there is currently little evidence to support its use in Americas. OBJECTIVES: The aim of this study was to provide information about effectiveness and safety of a standardised MA intralesional infiltration technique for the treatment of CL. METHODS: It is a single-arm phase II clinical trial conducted at a Brazilian referral centre. CL cases with parasitological confirmation presenting a maximum of three CL-compatible skin lesions were treated with weekly MA intralesional infiltration by using a validated technique, up to a maximum of eight infiltrations. RESULTS: A total of 53 patients (62 lesions) were included. Overall, patients received a median of seven infiltrations (IQR25-75% 5-8) over a median treatment period of 43 days (IQR25-75% 28-52 days). The definitive cure rate at D180 was 87% (95% CI:77-96%). The majority of adverse events were local, with mild or moderate intensity. Bacterial secondary infection of the lesion site was observed in 13% of the treated patients, beside two intensity-three adverse events (hypersensitivity reactions).
Subject(s)
Antiprotozoal Agents/administration & dosage , Leishmaniasis, Cutaneous/drug therapy , Meglumine/administration & dosage , Organometallic Compounds/administration & dosage , Adolescent , Adult , Aged , Antiprotozoal Agents/adverse effects , Brazil , Female , Humans , Injections, Intralesional , Leishmaniasis, Cutaneous/physiopathology , Male , Meglumine/adverse effects , Meglumine Antimoniate , Middle Aged , Organometallic Compounds/adverse effects , Treatment Outcome , Young AdultABSTRACT
Este trabajo utilizó un modelo macrófago humano-amastigote como herramienta para recrear in vitro la infección causada por aislados de pacientes con fracaso terapéutico y valorar su utilidad en la identificación de aislados de Leishmania con fenotipo quimio-resistente. Objetivos: (1) Evaluar un modelo in vitro de macrófago humano-amastigote y (2) Determinar su utilidad en la identificación de aislados de Leishmania con fenotipo quimio-resistente. Métodos: Se evaluó un protocolo de purificación basado en la capacidad de los monocitos de adherirse al plástico. Monocitos purificados de sangre humana fueron infectados con promastigotes metacíclicos de especies de referencia y aislados de Leishmania de tres pacientes con falla terapéutica a antimoniales. Se determinó el porcentaje de infección inicial y el efecto leishmanicida de glucantime, anfotericinaB y pentamidina; se correlacionó la capacidad leishmanicida con los niveles de producción de óxido nítrico en cada condición estudiada. Resultados: Los resultados sugieren que el modelo macrófago humano-amastigote empleado recrea in vitro la infección causada por especies de referencia, o con aislados de pacientes con fracaso terapéutico. Adicionalmente sugieren que en monocitos infectados (1) con el aislado VE98MR no puede definirse una IC50 para glucantime ni para pentamidina y (2) con el aislado VE96ZC no puede definirse una IC50 para glucantime mas si para pentamidina. De igual forma, se evidencia una disminución efectiva del porcentaje de infección susceptible a anfotericina-B, para todos los aislados y cepas de referencia. El efecto leishmanicida no se correlaciona con aumentos significativos de la producción de óxido nítrico. Conclusiones: El modelo macrófago humano-amastigote empleado constituye una prueba de concepto que permitió identificar como aislados potencialmente quimio-resistentes a L. (L.) amazonensis (VE98MR) y L. (L.) mexicana (VE96ZC), mas no al aislado L. (L.) amazonensis (VE2000MM)(AU)
This work used a human-amastigote macrophage model as a tool to recreate in vitro infection caused by isolates from patient's with therapeutic failure and assess its usefulness in the identification of chemo-resistant Leishmania isolates. Objectives: (1) Evaluate in vitro a human-amastigote macrophage model and (2) determine its usefulness in the identification of Leishmania isolates with chemo-resistant phenotype. Methods: A purification protocol based on the ability of monocytes to adhere to plastic was evaluated. Monocytes purified from human blood were infected with metacyclic promastigotes of reference species and Leishmania isolates from three patients with antimonial therapeutic failure. The percentage of initial infection and the leishmanicidal effect of glucantime, amphotericin-B and pentamidine were determined; the leishmanicidal capacity was correlated with the levels of nitric oxide production in each condition studied. Results: Results suggest that the human-amastigote macrophage model recreates in vitro the infection caused by reference species, or isolates from patients with therapeutic failure. In addition, they suggest that (1) an effective IC50 for glucantime and pentamidine could not be defined in monocytes infected with the isolate VE98MR and (2) an effective IC50 for pentamidine but nor for glucantime could be defined in monocytes infected with the isolate VE96ZC. On the contrary, an effective decrease in the percentage of infection susceptible to amphotericin-B was observed for all isolates and reference strains. The leishmanicidal effect did not correlate with significant increases in nitric oxide production. Conclusion: The human-amastigote macrophage model used constitutes a proof of concept to identify as potentially chemo-resistant isolates L. (L.) amazonensis (VE98MR) and L. (L.) mexicana (VE96ZC), but not L (L.) amazonensis (VE2000MM)(AU)
Subject(s)
Humans , Male , Female , In Vitro Techniques/methods , Leishmaniasis, Cutaneous/physiopathology , Leishmaniasis, Cutaneous/epidemiology , Leishmaniasis, Cutaneous/virology , Tropical Medicine , Public Health , Drug Therapy , Macrophage ActivationABSTRACT
We evaluated the importance of neutrophils in the development of chronic lesions caused by L. Viannia spp. using the hamster as experimental model of American Cutaneous Leishmaniasis (ACL). Neutrophils infiltrated the lesion within the first six hours post-infection. Inhibition of this early infiltration using a polyclonal antibody or cyclophosphamide was associated with transient parasite control but the protective effect vanished when lesions became clinically apparent. At lesion onset (approximately 10 days p.i.), there was an increased proportion of both uninfected and infected macrophages, and subsequently a second wave of neutrophils infiltrated the lesion (after 19 days p.i.) This second neutrophil infiltration was associated with lesion necrosis and ulceration (R2 = 0.75) and maximum parasite burden. Intradermal delivery of N-formylmethionyl-leucyl-phenylalanine (fMLP), aimed to increase neutrophil infiltration, resulted in larger lesions with marked necrosis and higher parasite burden than in mock treated groups (p<0.001 each). In contrast, reduced neutrophil infiltration via cyclophosphamide-mediated depletion led to more benign lesions and lower parasite loads compared to controls (p<0.001 each). Neutrophils of the second wave expressed significantly lower GM-CSF, reactive oxygen species and nitric oxide than those of the first wave, suggesting that they had less efficient anti-leishmania activity. However, there was increased inflammatory cytokines and expression of neutrophil proteases (myeloperoxidase, cathepsin G and elastase) in lesions during the second wave of neutrophil infiltration compared with the levels reached during the first wave (6h p.i.). This suggests that augmented neutrophil proteases and inflammatory cytokines during the secondary wave of neutrophils could contribute to skin inflammation, ulceration and necrosis in ACL. The overall results indicate that neutrophils were unable to clear the infection in this model, and that the second wave of neutrophils played an important role in the severity of ACL.
Subject(s)
Inflammation/blood , Leishmaniasis, Cutaneous/blood , Necrosis/blood , Neutrophil Infiltration , Animals , Cricetinae , Disease Models, Animal , Female , Humans , Inflammation/parasitology , Inflammation/physiopathology , Leishmania/pathogenicity , Leishmaniasis, Cutaneous/parasitology , Leishmaniasis, Cutaneous/physiopathology , Macrophages/pathology , Necrosis/parasitology , Necrosis/physiopathology , Neutrophils/pathology , Nitric Oxide/metabolism , Parasite Load , Reactive Oxygen Species/metabolism , United StatesABSTRACT
Cutaneous leishmaniasis (CL) is the most common form of the leishmaniasis in humans. Ulcerative painless skin lesions are predominant clinical features of CL. Wider data indicate pain accompanies human leishmaniasis, out with areas of painless ulcerative lesions per se. In rodents, Leishmania (L.) major infection induces nociceptive behaviors that correlate with peripheral cytokine levels. However, the role of the spinal cord in pain processing after Leishmania infection has not been investigated. Balb/c mice received intraplantar (i.pl.) injection of Leishmania (L). amazonensis and hyperalgesia, edema, parasitism, and spinal cord TNFα, TNFR1 and TNFR2 mRNA expression, and NFκB activation were evaluated. The effects of intrathecal (i.t.) injection of morphine, TNFα, TNFα inhibitors (etanercept and adalimumab) and NFκB inhibitor (PDTC) were investigated. The present study demonstrates that Leishmania (L.) amazonensis infection in balb/c mice induces chronic mechanical and thermal hyperalgesia in an opioid-sensitive manner. Spinal cord TNFα mRNA expression increased in a time-dependent manner, peaking between 30 and 40 days after infection. At the peak of TNFα mRNA expression (day 30), there was a concomitant increase in TNFR1 and TNFR2 mRNA expression. TNFα i.t. injection enhanced L. (L.) amazonensis-induced hyperalgesia. Corroborating a role for TNFα in L. (L.) amazonensis-induced hyperalgesia, i.t. treatment with the TNFα inhibitors, etanercept and adalimumab inhibited the hyperalgesia. L. (L.) amazonensis also induced spinal cord activation of NFκB, and PDTC (given i.t.), also inhibited L. (L.) amazonensis-induced hyperalgesia, and spinal cord TNFα, TNFR1 and TNFR2 mRNA expression. Moreover, L. (L.) amazonensis-induced spinal cord activation of NFκB was also inhibited by etanercept and adalimumab as well as PDTC i.t. TREATMENT: These results demonstrate that endogenous spinal cord TNFα and NFκB activation contribute to L. (L.) amazonensis-induced hyperalgesia in mice. Thus, spinal cord TNFα and NFκB are potential therapeutic targets for Leishmania infection-induced pain.
Subject(s)
Hyperalgesia/parasitology , Leishmania mexicana/physiology , Leishmaniasis, Cutaneous/parasitology , NF-kappa B/metabolism , Spinal Cord/physiopathology , Tumor Necrosis Factor-alpha/metabolism , Adalimumab/administration & dosage , Adalimumab/therapeutic use , Animals , Etanercept/administration & dosage , Etanercept/therapeutic use , Hyperalgesia/drug therapy , Hyperalgesia/metabolism , Hyperalgesia/physiopathology , Leishmaniasis, Cutaneous/drug therapy , Leishmaniasis, Cutaneous/physiopathology , Male , Mice, Inbred BALB C , Morphine/therapeutic use , NF-kappa B/antagonists & inhibitors , NF-kappa B/genetics , Parasite Load , Pyrrolidines/administration & dosage , Pyrrolidines/therapeutic use , RNA, Messenger/metabolism , Receptors, Tumor Necrosis Factor, Type I/genetics , Receptors, Tumor Necrosis Factor, Type I/metabolism , Receptors, Tumor Necrosis Factor, Type II/genetics , Receptors, Tumor Necrosis Factor, Type II/metabolism , Spinal Cord/metabolism , Thiocarbamates/administration & dosage , Thiocarbamates/therapeutic use , Tumor Necrosis Factor-alpha/administration & dosage , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Tumor Necrosis Factor-alpha/geneticsABSTRACT
BACKGROUND: The treatment for leishmaniasis is currently based on pentavalent antimonials and amphotericin B; however, these drugs result in numerous adverse side effects. The lack of affordable therapy has necessitated the urgent development of new drugs that are efficacious, safe, and more accessible to patients. Natural products are a major source for the discovery of new and selective molecules for neglected diseases. In this paper, we evaluated the effect of apigenin on Leishmania amazonensis in vitro and in vivo and described the mechanism of action against intracellular amastigotes of L. amazonensis. METHODOLOGY/PRINCIPAL FINDING: Apigenin reduced the infection index in a dose-dependent manner, with IC50 values of 4.3 µM and a selectivity index of 18.2. Apigenin induced ROS production in the L. amazonensis-infected macrophage, and the effects were reversed by NAC and GSH. Additionally, apigenin induced an increase in the number of macrophages autophagosomes after the infection, surrounding the parasitophorous vacuole, suggestive of the involvement of host autophagy probably due to ROS generation induced by apigenin. Furthermore, apigenin treatment was also effective in vivo, demonstrating oral bioavailability and reduced parasitic loads without altering serological toxicity markers. CONCLUSIONS/SIGNIFICANCE: In conclusion, our study suggests that apigenin exhibits leishmanicidal effects against L. amazonensis-infected macrophages. ROS production, as part of the mechanism of action, could occur through the increase in host autophagy and thereby promoting parasite death. Furthermore, our data suggest that apigenin is effective in the treatment of L. amazonensis-infected BALB/c mice by oral administration, without altering serological toxicity markers. The selective in vitro activity of apigenin, together with excellent theoretical predictions of oral availability, clear decreases in parasite load and lesion size, and no observed compromises to the overall health of the infected mice encourage us to supports further studies of apigenin as a candidate for the chemotherapeutic treatment of leishmaniasis.
Subject(s)
Antipruritics/administration & dosage , Apigenin/administration & dosage , Autophagy/drug effects , Leishmania/physiology , Leishmaniasis, Cutaneous/drug therapy , Leishmaniasis, Cutaneous/physiopathology , Reactive Oxygen Species/immunology , Animals , Drug Evaluation, Preclinical , Female , Humans , Leishmania/drug effects , Leishmaniasis, Cutaneous/immunology , Leishmaniasis, Cutaneous/parasitology , Macrophages/drug effects , Macrophages/immunology , Male , Mice , Mice, Inbred BALB CABSTRACT
Leishmaniasis is an infectious disease caused by protozoa of the genus Leishmania transmitted by insects of the genus Lutzomyia sp. or Phlebotomus sp. The main syndromes are cutaneous leishmaniasis, mucocutaneous leishmaniasis, visceral leishmaniasis (kala-azar) and post-kala-azar dermal leishmaniasis. This article reviews kidney involvement in cutaneous and visceral leishmaniasis, highlighting the aspects of their pathophysiology, clinical manifestations, histopathological findings, outcome and treatment.
Subject(s)
Humans , Kidney Diseases/parasitology , Leishmaniasis, Cutaneous/complications , Leishmaniasis, Visceral/complications , Kidney Diseases/pathology , Kidney Diseases/physiopathology , Leishmaniasis, Cutaneous/pathology , Leishmaniasis, Cutaneous/physiopathology , Leishmaniasis, Visceral/pathology , Leishmaniasis, Visceral/physiopathologyABSTRACT
Leishmaniasis is an infectious disease caused by protozoa of the genus Leishmania transmitted by insects of the genus Lutzomyia sp. or Phlebotomus sp. The main syndromes are cutaneous leishmaniasis, mucocutaneous leishmaniasis, visceral leishmaniasis (kala-azar) and post-kala-azar dermal leishmaniasis. This article reviews kidney involvement in cutaneous and visceral leishmaniasis, highlighting the aspects of their pathophysiology, clinical manifestations, histopathological findings, outcome and treatment.
Subject(s)
Kidney Diseases/parasitology , Leishmaniasis, Cutaneous/complications , Leishmaniasis, Visceral/complications , Humans , Kidney Diseases/pathology , Kidney Diseases/physiopathology , Leishmaniasis, Cutaneous/pathology , Leishmaniasis, Cutaneous/physiopathology , Leishmaniasis, Visceral/pathology , Leishmaniasis, Visceral/physiopathologyABSTRACT
Disease progression in response to infection can be strongly influenced by both pathogen burden and infection-induced immunopathology. While current therapeutics focus on augmenting protective immune responses, identifying therapeutics that reduce infection-induced immunopathology are clearly warranted. Despite the apparent protective role for murine CD8⺠T cells following infection with the intracellular parasite Leishmania, CD8⺠T cells have been paradoxically linked to immunopathological responses in human cutaneous leishmaniasis. Transcriptome analysis of lesions from Leishmania braziliensis patients revealed that genes associated with the cytolytic pathway are highly expressed and CD8⺠T cells from lesions exhibited a cytolytic phenotype. To determine if CD8⺠T cells play a causal role in disease, we turned to a murine model. These studies revealed that disease progression and metastasis in L. braziliensis infected mice was independent of parasite burden and was instead directly associated with the presence of CD8⺠T cells. In mice with severe pathology, we visualized CD8⺠T cell degranulation and lysis of L. braziliensis infected cells. Finally, in contrast to wild-type CD8⺠T cells, perforin-deficient cells failed to induce disease. Thus, we show for the first time that cytolytic CD8⺠T cells mediate immunopathology and drive the development of metastatic lesions in cutaneous leishmaniasis.
Subject(s)
Cytotoxicity, Immunologic , Disease Models, Animal , Leishmania braziliensis/immunology , Leishmaniasis, Cutaneous/immunology , Skin/immunology , T-Lymphocytes, Cytotoxic/immunology , Animals , Bacterial Proteins/genetics , Bacterial Proteins/metabolism , Brazil , Disease Progression , Gene Expression Profiling , Homeodomain Proteins/genetics , Homeodomain Proteins/metabolism , Humans , Leishmania braziliensis/isolation & purification , Leishmaniasis, Cutaneous/parasitology , Leishmaniasis, Cutaneous/pathology , Leishmaniasis, Cutaneous/physiopathology , Leishmaniasis, Diffuse Cutaneous/etiology , Mice , Mice, Inbred BALB C , Mice, Inbred C57BL , Mice, Knockout , Mice, Transgenic , Skin/parasitology , Skin/pathology , Specific Pathogen-Free Organisms , T-Lymphocytes, Cytotoxic/parasitology , T-Lymphocytes, Cytotoxic/pathologyABSTRACT
Several reports have shown that cutaneous leishmaniasis lesions are painless, suggesting that Leishmania infection interferes with pain perception. Comparisons of inflammation-induced hyperalgesia between BALB/c and C57BL/6 mice have been little explored in the literature, and comparative data regarding nociception in leishmaniasis are non-existent. In susceptible BALB/c mice and resistant C57BL/6 mice that were intradermally inoculated with a low dose of Leishmania major in the ear, we investigated the variation in nociception over a 12-wk period post-infection and this variation's association with the structure of nerve fibres and the presence of endogenous cytokines that are classically considered hyper- or hypo-nociceptive. Infected BALB/c mice presented susceptibility and severe lesions. Infected C57BL/6 mice exhibited resistance and healing lesions. The immune response involved pro- and anti-inflammatory cytokine secretion, respectively. The infection-induced hypoalgesia in BALB/c mice after wks 9 was accompanied by decreased levels of IL-6 and IL-10 in ear tissue with intact nerves. C57BL/6 mice showed short-lived hyperalgesia in wks 2, which was related to increased local levels of IL-6, KC/CXCL-1, TNF-α and IL-10 and a decrease in nerve density. The increase in pro-inflammatory cytokine IL-6, KC/CXCL-1 and TNF-α levels during hyperalgesia suggested a role for these mediators in afferent nerve sensitisation, which was secondary to the inflammatory damage of nerve fibres stained by PGP 9.5. In contrast, the mechanisms of hypoalgesia may include the downregulation of cytokines, the preservation of the structure of nerve endings, and as yet uninvestigated unidentified differences in neurotransmitter release or a direct role of the parasites in the context of the progressive and permissive inflammatory response of BALB/c mice.
Subject(s)
Cytokines/analysis , Ear, External/parasitology , Leishmania major/immunology , Leishmaniasis, Cutaneous/physiopathology , Nociception/physiology , Animals , Cytokines/metabolism , Down-Regulation , Ear, External/immunology , Ear, External/innervation , Female , Immunohistochemistry , Leishmania major/pathogenicity , Leishmaniasis, Cutaneous/complications , Leishmaniasis, Cutaneous/immunology , Mice , Mice, Inbred BALB C , Mice, Inbred C57BL , Nociceptive Pain/etiology , Nociceptive Pain/immunology , Nociceptive Pain/physiopathology , Pain Threshold/physiology , Ubiquitin Thiolesterase/analysisABSTRACT
BACKGROUND: Renal evaluation studies are rare in American Cutaneous Leishmaniasis (ACL). The aim of this study is to investigate whether specific treatment reverts ACL-associated renal dysfunction. METHODS: A prospective study was conducted with 37 patients with ACL. Urinary concentrating and acidification ability was assessed before and after treatment with pentavalent antimonial. RESULTS: The patients mean age was 35.6 ± 12 years and 19 were male. Before treatment, urinary concentrating defect (U/Posm <2.8) was identified in 27 patients (77%) and urinary acidification defect in 17 patients (46%). No significant glomerular dysfunction was observed before and after specific ACL treatment. There was no reversion of urinary concentrating defects, being observed in 77% of the patients before and in 88% after treatment (p = 0.344). Urinary acidification defect was corrected in 9 patients after treatment, reducing its prevalence from 40% before to only 16% after treament, (p = 0.012). Microalbuminuria higher than 30 mg/g was found in 35% of patients before treatment and in only 8% after treatment. Regarding fractional excretion of sodium, potassium, calcium, phosphorus and magnesium, there was no significant difference between pre and post-treatment period. CONCLUSION: As previously described, urinary concentrating and acidification defects were found in an important number of patients with ACL. Present results demonstrate that only some patients recover urinary acidification capacity, while no one returned to normal urinary concentration capacity.
Subject(s)
Antiprotozoal Agents/therapeutic use , Kidney/physiology , Leishmaniasis, Cutaneous/drug therapy , Meglumine/therapeutic use , Organometallic Compounds/therapeutic use , Adult , Antiprotozoal Agents/pharmacology , Female , Humans , Kidney/drug effects , Kidney Diseases/diagnosis , Kidney Diseases/physiopathology , Kidney Diseases/urine , Leishmaniasis, Cutaneous/physiopathology , Leishmaniasis, Cutaneous/urine , Male , Meglumine/pharmacology , Meglumine Antimoniate , Middle Aged , Organometallic Compounds/pharmacology , Prospective Studies , Treatment Outcome , Young AdultABSTRACT
American cutaneous leishmaniasis (ACL) has different clinical manifestations and these manifestations are dependent on the immunological status of the host. As CD4(+) and CD8(+) T cells and their mediators play a fundamental role in the host response to Leishmania and there is also a search for antigenic molecules to be used as future vaccines and tools for prognostic tests, this study characterized ACL patients' immune response after stimulation with soluble and insoluble fractions of L. (V.) braziliensis. We demonstrated a prevailing production of the Th2 cytokines, IL-4 and IL-10 and a specific production of IFN-γ and TNF-α in patients before treatment. There was also a predominance of CD4(+) T cells and a small percentage CD8(+) T cells. The insoluble antigenic fraction primarily stimulated CD4(+) T cells, while the soluble antigenic fraction showed a mixed profile, with CD4(+) T cells being the main responsible for Th2 cytokines and CD8(+) T cells for Th1 cytokines. Therefore, our results showed that a down-modulation of the Th1 type of response occurs in the initial phase of L. braziliensis disease, being the antigenic fractions capable of stimulating a specific immune response.
Subject(s)
Antigens, Protozoan/immunology , Cytokines/metabolism , Leishmania braziliensis/immunology , Leishmania braziliensis/pathogenicity , Leishmaniasis, Cutaneous/immunology , Th2 Cells/immunology , Adolescent , Adult , Aged , Aged, 80 and over , Antigens, Protozoan/chemistry , CD4-Positive T-Lymphocytes/immunology , Female , Flow Cytometry , Humans , Interleukin-10/metabolism , Interleukin-4/metabolism , Leishmaniasis, Cutaneous/parasitology , Leishmaniasis, Cutaneous/physiopathology , Male , Middle Aged , Time Factors , Young AdultABSTRACT
Leishmania (Viannia) shawi was recently characterized and few studies concerning modifications in cellular and humoral immune responses in experimental leishmaniasis have been conducted. In this work, immunopathological changes induced by L. shawi in chronically infected BALB/c mice were investigated. Infected BALB/c mice developed increased lesion size associated with strong inflammatory infiltrate diffusely distributed in the dermis, with highly infected macrophages. The humoral immune response was predominantly directed toward the IgG1 isotype. The functional activity of CD4(+) and CD8(+) T cells showed significantly increased TNF-alpha mRNA levels associated with reduced IFN-gamma expression by CD4(+) T cells and the double negative (dn) CD4CD8 cell subset. High IL-4 levels expressed by CD8(+) T cells and dnCD4CD8 and TGF-beta by CD4(+) and CD8(+) T cells were detected, while IL-10 was highly expressed by all three cell subpopulations. Taken together, these results show an evident imbalance between TNF-alpha and IFN-gamma that is unfavorable to amastigote replication control. Furthermore, L. shawi seems to regulate different cell populations to express deactivating cytokines to avoid its own destruction. This study indicates BALB/c mice as a potentially good experimental model for further studies on American cutaneous leishmaniosis caused by L. shawi.
Subject(s)
Antibodies, Protozoan/blood , CD4-Positive T-Lymphocytes/immunology , CD8-Positive T-Lymphocytes/immunology , Disease Models, Animal , Leishmania , Leishmaniasis, Cutaneous , Animals , Cytokines/metabolism , Dermis/immunology , Dermis/parasitology , Dermis/pathology , Humans , Immunoglobulin G/blood , Leishmania/classification , Leishmania/growth & development , Leishmania/immunology , Leishmania/pathogenicity , Leishmaniasis, Cutaneous/immunology , Leishmaniasis, Cutaneous/parasitology , Leishmaniasis, Cutaneous/pathology , Leishmaniasis, Cutaneous/physiopathology , Macrophages/parasitology , Mice , Mice, Inbred BALB CABSTRACT
To determine whether disease outcomes and clades of Leishmania braziliensis genotypes are associated, we studied geographic clustering of clades and most severe disease outcomes for leishmaniasis during 1999-2003 in Corte de Pedra in northeastern Brazil. Highly significant differences were observed in distribution of mucosal leishmaniasis versus disseminated leishmaniasis (DL) (p<0.0001). Concordance was observed between distribution of these disease forms and clades of L. braziliensis genotypes shown to be associated with these disease forms. We also detected spread of DL over this region and an inverse correlation between frequency of recent DL diagnoses and distance to a previous DL case. These findings indicate that leishmaniasis outcomes are distributed differently within transmission foci and show that DL is rapidly spreading in northeastern Brazil.
Subject(s)
Leishmania braziliensis/classification , Leishmaniasis, Cutaneous/epidemiology , Leishmaniasis, Cutaneous/physiopathology , Agriculture , Animals , Brazil/epidemiology , Cluster Analysis , Genotype , Humans , Incidence , Leishmania braziliensis/genetics , Leishmaniasis, Cutaneous/parasitology , Leishmaniasis, Diffuse Cutaneous/epidemiology , Leishmaniasis, Diffuse Cutaneous/parasitology , Leishmaniasis, Diffuse Cutaneous/physiopathology , Leishmaniasis, Mucocutaneous/epidemiology , Leishmaniasis, Mucocutaneous/parasitology , Leishmaniasis, Mucocutaneous/physiopathology , PrevalenceABSTRACT
Neutrophils are involved in the initial steps of most responses to pathogens. In the present study, we evaluated the effects of the interaction of apoptotic vs. necrotic human neutrophils on macrophage infection by Leishmania amazonensis. Phagocytosis of apoptotic, but not viable, neutrophils by Leishmania-infected macrophages led to an increase in parasite burden via a mechanism dependent on TGF-beta1 and PGE2. Conversely, infected macrophages' uptake of necrotic neutrophils induced killing of L. amazonensis. Leishmanicidal activity was dependent on TNF-alpha and neutrophilic elastase. Nitric oxide was not involved in the killing of parasites, but the interaction of necrotic neutrophils with infected macrophages resulted in high superoxide production, a process reversed by catalase, an inhibitor of reactive oxygen intermediate production. Initial events after Leishmania infection involve interactions with neutrophils; we demonstrate that phagocytosis of these cells in an apoptotic or necrotic stage can influence the outcome of infection, driving either parasite survival or destruction.
Subject(s)
Leishmaniasis, Cutaneous/physiopathology , Macrophages/parasitology , Neutrophils/immunology , Neutrophils/physiology , Animals , Apoptosis , Catalase/pharmacology , Cost of Illness , Dinoprostone/physiology , Humans , Leishmania mexicana/pathogenicity , Leishmania mexicana/physiology , Leishmaniasis, Cutaneous/pathology , Necrosis , Neutrophils/pathology , Phagocytosis , Superoxides/metabolism , Transforming Growth Factor beta1/physiologyABSTRACT
As leishmanioses são zoonoses causadas por protozoários e podem ser divididas em dois grupos: leishmaniose cutaneomucosa e leishmaniose visceral, essa última também conhecida como calazar. O diagnóstico é feito com base em dados clínicos e epidemiológicos, sendo confirmado através de exames laboratoriais específicos. As drogas de escolha para o tratamento são os antimoniais.
Subject(s)
Leishmaniasis, Visceral , Leishmaniasis, Cutaneous/diagnosis , Leishmaniasis, Cutaneous/physiopathology , Leishmaniasis, Cutaneous/therapy , EukaryotaABSTRACT
The role of cytokines in Leishmania amazonensis experimental infection has not been as well studied as in Leishmania major infection model. Here we investigated the role of interleukin (IL)-4 and PGE(2) in L. amazonensis infection of susceptible BALB/c mice. IL-4 deficient (-/-) or wild-type (+/+) BALB/c mice were infected with different inocula of L. amazonensis. Two weeks after infection with 5x10(6) promastigotes/footpad, the production of interferon (IFN)-gamma upon L. amazonensis antigen stimulation was significantly higher in lymph node cell cultures of IL-4-/- mice than in IL-4+/+ mice. The levels of anti-leishmania IgG2a antibodies were also significantly higher in serum from IL-4-/- mice. In contrast, the levels of IgG1 antibodies were increased in IL-4+/+ mice and almost undetectable in IL-4-/- mice. Despite the increased Th1 response, lesions of IL-4-/- BALB/c mice progressed similarly to those of IL-4+/+ mice upon infection with the 5x10(6) inoculum. However, IL-4-/- mice developed smaller lesions upon infection with 10(5), 10(4) or 10(3) parasites than IL-4+/+ mice. The resistance of IL-4-/- correlated with higher Th1 response, compared to IL-4+/+ upon infection with 10(4)L. amazonensis. IL-4+/+ mice treated with indomethacin, an inhibitor of PGE(2) synthesis, during the first 3weeks of infection developed smaller lesions and lower parasitic load when compared to the control group. The lesions of indomethacin-treated groups contained mostly macrophages without vacuoles and small or absent necrotic areas. These results indicate that IL-4 and PGE(2) are susceptibility factors to L. amazonensis infection.
Subject(s)
Dinoprostone/metabolism , Interleukin-4/metabolism , Leishmania mexicana , Leishmaniasis, Cutaneous/immunology , Animals , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Disease Susceptibility , Female , Humans , Indomethacin/therapeutic use , Interferon-gamma/biosynthesis , Leishmania mexicana/immunology , Leishmaniasis, Cutaneous/drug therapy , Leishmaniasis, Cutaneous/parasitology , Leishmaniasis, Cutaneous/physiopathology , Mice , Mice, Inbred BALB CABSTRACT
The immune mechanisms that underlie resistance and susceptibility to leishmaniasis are not completely understood for all species of Leishmania. It is becoming clear that the immune response, the parasite elimination by the host and, as a result, the outcome of the disease depend both on the host and on the species of the infecting Leishmania. Here, we analyzed the outcome of the infection of BALB/c mice with L. guyanensis in vivo and in vitro. We showed that BALB/c mice, which are a prototype of susceptible host for most species of Leishmania, dying from these infections, develop insignificant or no cutaneous lesions and eliminate the parasite when infected with promastigotes of L. guyanensis. In vitro, we found that thioglycollate-elicited BALB/c peritoneal macrophages, which are unable to eliminate L. amazonensis without previous activation with cytokines or lipopolysaccharide, can kill L. guyanensis amastigotes. This is the first report showing that infection of peritoneal macrophages with stationary phase promastigotes efficiently triggers innate microbicidal mechanisms that are effective in eliminating the amastigotes, without exogenous activation. We demonstrated that L. guyanensis amastigotes die inside the macrophages through an apoptotic process that is independent of nitric oxide and is mediated by reactive oxygen intermediates generated in the host cell during infection. This innate killing mechanism of macrophages may account for the resistance of BALB/c mice to infection by L. guyanensis.
Subject(s)
Apoptosis , Leishmania guyanensis/pathogenicity , Leishmaniasis, Cutaneous/immunology , Macrophages/immunology , Macrophages/parasitology , Respiratory Burst , Animals , Cells, Cultured , Leishmania guyanensis/growth & development , Leishmaniasis, Cutaneous/physiopathology , Macrophage Activation/immunology , Macrophages, Peritoneal/immunology , Macrophages, Peritoneal/parasitology , Mice , Mice, Inbred BALB C , Reactive Oxygen Species/metabolismABSTRACT
The role of plasminogen, the zymogenic form of the serine protease plasmin, was investigated in the infection of Leishmania mexicana in plasminogen-deficient (plg(-/-)) and Plg wild-type (plg(+/+)) mice. Differences in the lesion size were observed between male plg(+/+) and plg(-/-) mice. However, these differences were not observed in female mice. In both genders, examination of the lesion tissues at 8 weeks post-infection showed differences in the immunoreactivity pattern with anti-Leishmania antibodies. The parasites were limited to isolated foci in the plg(-/-) mice lesion, in contrast to the scattered pattern observed in plg(+/+) mice. These results support the hypothesis that the interaction of the parasite with the host plasminogen-plasmin system might contribute to the virulence of L. mexicana.
Subject(s)
Host-Parasite Interactions/physiology , Leishmania mexicana/pathogenicity , Leishmaniasis, Cutaneous/pathology , Leishmaniasis, Cutaneous/physiopathology , Plasminogen/deficiency , Animals , Female , Immunohistochemistry , Leishmania mexicana/immunology , Leishmaniasis, Cutaneous/immunology , Male , Mice , Sex FactorsABSTRACT
A Leishmaniose Tegumentar Americana (LTA) é uma doença infecciosa, não contagiosa, causada por protozoários do gênero Leishmania, que acomete pele e mucosas. O homem é infectado através da picada dos flebotomíneos e na maioria das vezes a doença apresenta-se como uma lesão ulcerada única. A confirmação do caso de LTA é realizada pelo diagnóstico clínico, epidemiológico e laboratorial. Relatamos três casos de LTA autóctones diagnosticados em 2002 e 2003 na cidade de Porto Alegre, RS. Evidenciamos a necessidade de atenção para a detecção de novos casos e o controle ambiental, já que segundo registros do Ministério de Saúde do Brasil, no período de 1997-1999, o Rio Grande do Sul não apresentou caso autóctone de LTA (AU)
American Cutaneous Leishmaniasis (ACL) is an infectious, non-contagious disease caused by a genus Leishmania Protozoa, which affects the skin and the mucosae. Man is infected by bites of phlebotominea and the disease presents mostly as a single ulcerated lesion. The confirmation of the case of ACL is performed by clinical, epidemiological and laboratory diagnosis. We report three cases of autochthonous ACL diagnosed in 2002 and 2003 in the city of Porto Alegre. We show the need to watch out for new cases and to perform environmental control, since, according to the records of the Brazilian Ministry of Health, during the 1997-1999 period, Rio Grande do Sul did not present autochthonous cases of ACL (AU)
Subject(s)
Humans , Male , Female , Adult , Middle Aged , Leishmaniasis, Cutaneous/epidemiology , Brazil/epidemiology , Leishmaniasis, Cutaneous/physiopathologyABSTRACT
A quantitative study was conducted on the density of Langerhans cells (LCs) CD1a+ in specimens obtained from patients with American tegumentary leishmaniasis (ATL) lesions without previous treatment, as well as from control healthy individuals. LC density was significantly higher among infected patients when compared to controls and also higher in longer term ones. Regarding parasite quantities, these were proportionally inverse and diminished in chronic patients. Localized cutaneous leishmaniasis (LCL) showed an increase in cell population when compared to diffuse cutaneous leishmaniasis (DCL). A tendency towards density increase was observed in LC Leishmania (Leishmania) amazonensis patients when compared to Leishmania (Viannia) sp. Regarding the delayed hypersensitivity test (DTH, Montenegro skin test), L. (L.) amazonensis demonstrated a peculiar behavior because it is a poor cell immune inducer, presenting--among LCL patients--higher density in negative Montenegro patients than in positive ones. Negative DTH responses are usually poor in LC, although this was not evidenced in this study, possibly due to cell reposition, in order to stimulate immune response. Such results confirm the important role of LC in ATL, while suggesting that L. (L.) amazonensis may be a good model for LC studies as APC in ATL, due to its spectral immunological and clinical behavior.